Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by MannKind
< Previous
1
2
3
Next >
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management
September 09, 2026
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind to Present at Upcoming Investor Conferences
September 02, 2026
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
August 05, 2026
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
July 29, 2026
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026
July 28, 2026
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Announces $50 Million Private Placement
July 24, 2026
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease
July 24, 2026
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D
June 23, 2026
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
June 05, 2026
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF
June 03, 2026
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval
May 29, 2026
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes
May 29, 2026
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind to Present at Jefferies Global Healthcare Conference
May 27, 2026
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems
May 27, 2026
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Reports First Quarter 2026 Financial Results and Provides Business Update
May 06, 2026
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
May 06, 2026
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
UTHR
MannKind to Report First Quarter 2026 Financial Results on May 6, 2026
April 29, 2026
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026
March 09, 2026
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Announces Settlement of Convertible Senior Notes
March 05, 2026
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind to Participate in Upcoming Investor Conferences
March 04, 2026
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 26, 2026
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 19, 2026
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
February 18, 2026
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)
February 09, 2026
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy
January 26, 2026
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Provides Business Updates and 2026 Growth Drivers
January 08, 2026
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Shares FUROSCIX® Business Updates
December 23, 2025
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease
December 01, 2025
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind to Present at the Jefferies Global Healthcare Conference
November 11, 2025
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease
November 10, 2025
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
